NanOss Bioactive With Autograft and Bone Marrow Aspirate in the Posterolateral Spine

January 2, 2017 updated by: Pioneer Surgical Technology, Inc.

A Prospective, Nonrandomized Study to Assess Lumbar Fusion With Instrumented Posterolateral Gutter Fusions Using NanOss Bioactive

The purpose of this study is to assess lumbar fusion using nanOss Bioactive bone void filler

Study Overview

Study Type

Interventional

Phase

  • Not Applicable

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

21 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Is at least 21 years of age and skeletally mature.
  2. Must have cervical disc disease (defined as neck pain of discogenic origin with degeneration of the disc confirmed by history and radiographic studies) at one level in the cervical spine between C3 to T1.
  3. Must have completed a minimum of six weeks of unsuccessful conservative, non-operative care or has the presence of progressive symptoms or signs of nerve root/spinal cord compression in the face of conservative treatment.
  4. Has pre-operative objective evidence of primary diagnosis confirmed by appropriate imaging studies (Anteroposterior/Lateral/Flexion/Extension X-rays & a recent MRI).
  5. Is willing and able to comply with all clinical investigation visits and procedures including screening treatment procedures, post-operative management, the follow-up schedule and completion of forms or questionnaires.
  6. Is able to understand and sign the patient information sheet/informed consent form.

Exclusion Criteria:

  1. Requires fusion at more than one level.
  2. Has had prior fusion at the level to be treated.
  3. Has a metabolic or systemic bone disorder.
  4. Has a disease that significantly inhibits bone healing (i.e., severe osteoporosis, osteomalacia, Paget's disease).
  5. Has a systemic or local infection (active or latent).
  6. Has acute or chronic infections in the surgical area (i.e., soft tissue infections; inflammatory, bacterial bone disorders, osteomyelitis).
  7. Chronic use of steroids, other than episodic use or inhaled corticosteroids.
  8. Has any significant general illness (i.e., HIV, active metastatic cancer of any type, uncontrolled diabetes Type I, dialysis dependent renal failure, symptomatic liver disease).
  9. Has a mental or physical condition that would limit the ability to comply with study requirements or would preclude accurate evaluation.
  10. Is immunocompromised or being treated with immunosuppressive agents (including chemotherapy or radiation treatment).
  11. Has documented allergies to hydroxyapatite or porcine collagen, PEEK, titanium, titanium alloy or tantalum.
  12. Is currently pregnant, or interested in becoming pregnant during the clinical investigation follow-up.
  13. Is a smoker.
  14. Is non-English speaking.
  15. Requires the use of a bone-growth stimulator.
  16. Is a prisoner.
  17. Is currently involved in another drug or device clinical investigation that may confound the clinical trial investigation

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Autograft bone
Experimental: nanOss with bone marrow aspirate

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Fusion at 12 months postoperatively.
Time Frame: 12 months
12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

October 1, 2011

Primary Completion (Anticipated)

September 1, 2014

Study Completion (Anticipated)

September 1, 2014

Study Registration Dates

First Submitted

December 3, 2013

First Submitted That Met QC Criteria

December 3, 2013

First Posted (Estimate)

December 9, 2013

Study Record Updates

Last Update Posted (Estimate)

January 4, 2017

Last Update Submitted That Met QC Criteria

January 2, 2017

Last Verified

January 1, 2017

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • 2010-02b

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Lumbar Spinal Stenosis Secondary to Other Disease

Clinical Trials on Autograft

3
Subscribe